Pistacia lentiscus resin regulates intestinal damage and inflammation in trinitrobenzene sulfonic acid-induced colitis

Journal of Medicinal Food

Volumn 14, Issue 11, 2011, Pages 1403-1411

  Gioxari, Aristea ^a   Kaliora, Andriana C ^a   Papalois, Apostolos ^b   Agrogiannis, George ^c   Triantafillidis, John K ^d   Andrikopoulos, Nikolaos K ^a  

^a HAROKOPIO UNIVERSITY   (Greece)

^b ELPEN Pharmaceuticals Co Inc   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d IASO GENERAL HOSPITAL   (Greece)

Author keywords

Crohn's disease; immunomodulation; oxidative stress; Pistacia lentiscus; rats

Indexed keywords

CORTISONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MALONALDEHYDE; PISTACIA LENTISCUS EXTRACT; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; DIGESTIVE SYSTEM INFLAMMATION; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; INTESTINE EPITHELIUM; INTESTINE INJURY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; INTESTINAL MUCOSA; MALE; MALONDIALDEHYDE; PISTACIA; PLANT EXTRACTS; RATS; RATS, WISTAR; RESINS, PLANT; TRINITROBENZENES; TUMOR NECROSIS FACTOR-ALPHA;

ANACARDIACEAE; PISTACIA LENTISCUS; RATTUS; RATTUS NORVEGICUS;

EID: 80755175250     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2010.0240     Document Type: Article

References (40)

1. Lakatos PL: Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006;12: 6102-6108. (Pubitemid 44688157)
2. Hendrickson BA, Gokhale R, Cho JH: Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-94.
3. Neuman MG: Immune dysfunction in inflammatory bowel disease. Transl Res 2007;149:173-186. (Pubitemid 46442010)
4. Grisham MB: Oxidants and free radicals in inflammatory bowel disease. Lancet 1994;344:859-861. (Pubitemid 24290387)
5. Al-Habbal MJ, Al-Habbal Z, Huwez FU: A double-blind controlled clinical trial of mastic and placebo in the treatment of duodenal ulcer. Clin Exp Pharmacol Physiol 1984;11:541-544. (Pubitemid 15190343)
6. Al-Said MS, Ageel AM, Parmar NS, Tarig M: Evaluation of mastic, a crude drug obtained from Pistacia lentiscus for gastric and duodenal anti-ulcer activity. J Ethnopharmacol 1986;15: 271-278. (Pubitemid 16082456)
7. Huwez FU, Al-Habbal MJ: Mastic in treatment of benign gastric ulcers. Gastroenterol Jpn 1986;21:273-274. (Pubitemid 16085667)
8. Paraschos S, Magiatis P, Mitakou S, Petraki K, Kalliaropoulos A, Maragkoudakis P, Mentis A, Sgouras D, Skaltsounis AL: In vitro and in vivo activities of Chios mastic gum extracts and constituents against Helicobacter pylori. Antimicrob Agents Chemother 2007;51:551-559.
9. Triantafyllou A, Chaviaras N, Sergentanis TN, Protopapa E, Tsaknis J: Chios mastic gum modulates serum biochemical parameters in a human population. J Ethnopharmacol 2007;111: 43-49. (Pubitemid 46482880)
10. Andrikopoulos NK, Kaliora AC, Assimopoulou AN, Papapeorgiou VP: Biological activity of some naturally occurring resins, gums and pigments against in vitro LDL oxidation. Phytother Res 2003;17:501-507. (Pubitemid 36605902)
11. Dedoussis GV, Kaliora AC, Psarras S, Chiou A, Mylona A, Papadopoulos NG, Andrikopoulos NK: Antiatherogenic effect of Pistacia lentiscus via GSH restoration and downregulation of CD36 mRNA expression. Atherosclerosis 2004;174:293-303. (Pubitemid 38597086)
12. Dimas K, Hatziantoniou S, Wyche JH, Pantazis P: A mastic gum extract induces suppression of growth of human colorectal tumor xenografts in immunodeficient mice. In Vivo 2009;23:63-68.
13. Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK: Chios mastic treatment of patients with active Crohn's disease. World J Gastroenterol 2007;13:748-753.
14. Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK: Alternations in the function of circulating mononuclear cells derived from patients with Crohn's disease treated with mastic. World J Gastroenterol 2007;13:6031-6036. (Pubitemid 350238271)
15. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R: A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404-409.
16. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
17. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803. (Pubitemid 19057602)
18. Pizarro TT, Arseneau KO, Bamias G, Cominelli F: Mouse models for the study of Crohn's disease. Trends Mol Med 2003;9:218-222. (Pubitemid 36713392)
19. Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Büschenfelde KH, Strober W, Kollias G: Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997;27:1743-1750. (Pubitemid 27302858)
20. Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, Fiocchi C: Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993;104:749-758. (Pubitemid 23059573)
21. Maeda M, Watanabe N, Neda H, Yamauchi N, Okamoto T, Sasaki H, Tsuji Y, Akiyama S, Tsuji N, Niitsu Y: Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 1992;14:451-461.
22. Papadakis KA, Targan SR: Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;19:1148-1157.
23. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P: Endoscopic and histological healing with infliximab antitumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-1034. (Pubitemid 29203012)
24. MacDonald TT, Monteleone G: Manipulation of cytokines in the management of patients with inflammatory bowel disease. Ann Med 2000;32:552-560.
25. Gross V, Andus T, Caesar I, Roth M, Schölmerich J: Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992;102:514-519.
26. Ina K, Kusugami K, Yamaguchi T, Imada A, Hosokawa T, Ohsuga M, Shinoda M, Ando T, Ito K, Yokoyama Y: Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am J Gastroenterol 1997;92:1342-1346. (Pubitemid 27328597)
27. Daig R, Andus T, Aschenbrenner E, Falk W, Schölmerich J, Gross V: Increased interleukin-8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996;38:216-222.
28. Sans M, Panés J, Ardite E, Elizalde JI, Arce Y, Elena M, Palac?́n A, Fernández-Checa JC, Anderson DC, Lobb R, Piqué JM: VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 1999;116: 874-883. (Pubitemid 29153535)
29. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-1142. (Pubitemid 28243898)
30. Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G: Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-1346. (Pubitemid 32322307)
31. Van Deventer SJ, Tami JA, Wedel MK: A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004;53:1646-5161.
32. Shanahan F: Probiotics in inflammatory bowel disease. Gut 2001;48:609.
33. Girgin F, Karaoglu O, Erkusx M, Tüzün S, Ozütemiz O, Dinçer C, Batur Y, Tanyalçin T: Effects of trimetazidine on oxidant/antioxidant status in trinitrobenzenesulfonic acid-induced chronic colitis. J Toxicol Environ Health A 2000;59:641-562.
34. Verspaget HW, Peña AS, Weterman IT, Lamers CB: Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content. Gut 1988;29:223-228. (Pubitemid 18078892)
35. Kaliora AC, Mylona A, Chiou A, Petsios DG, Andrikopoulos NK: Detection and identification of simple phenolics in Pistacia lentiscus resin. J Liquid Chromatogr Relat Technol 2004;27: 289-300. (Pubitemid 38294977)
36. Camacho-Barquero L, Villegas I, Sánchez-Calvo JM, Talero E, Sánchez-Fidalgo S, Motilva V, Alarcón de la Lastra C: Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 2007;7:333-342. (Pubitemid 46186172)
37. Camuesco D, Comalada M, Rodr?́guez-Cabezas ME, Nieto A, Lorente MD, Concha A, Zarzuelo A, Gálvez J: The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol 2004;143:908-918. (Pubitemid 39664850)
38. Nieto N, Fernandez MI, Torres MI, Rios A, Suarez MD, Gil A: Dietary monounsaturated n-3 and n-6 long-chain polyunsaturated fatty acids affect cellular antioxidant defense system in rats with experimental ulcerative colitis induced by trinitrobenzene sulfonic acid. Dig Dis Sci 1998;43:2676-2687. (Pubitemid 29034922)
39. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB: Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 2004;17:259-275.
40. Videla S, Vilaseca J, Antol?́n M, Garc?́a-Lafuente A, Guarner F, Crespo E, Casalots J, Salas A, Malagelada JR: Dietary inulin improves distal colitis induced by dextran-sodium sulfate in the rat. Am J Gastroenterol 2001;96:1486-1493. (Pubitemid 32455079)